SO
SPRO icon

STRS Ohio’s Spero Therapeutics SPRO Stock Holding History

STRS Ohio’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,100
Closed -$79K – 2269
2020
Q3 		$79K Hold
7,100
– – ﹤0.01% 1888
2020
Q2 		$96K Buy
+7,100
New +$79.7K ﹤0.01% 1797
2018
Q3 		– Sell
-1,700
Closed -$19.7K – 2176
2018
Q2 		$24K Hold
1,700
– – ﹤0.01% 2048
2018
Q1 		$24K Hold
1,700
– – ﹤0.01% 1809
2017
Q4 		$19K Buy
+1,700
New +$20.9K ﹤0.01% 1821

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVAX
Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

STRS Ohio's SPRO Position: Q4 2020 in Review

STRS Ohio sold out of Spero Therapeutics (SPRO) in Q4 2020, closing a stake of 7,100 shares — an estimated $79K sold.

STRS Ohio first reported a position in SPRO in Q4 2017 and held it in 5 quarters. The position peaked at $96K in Q2 2020. 89 funds tracked by Wall St. Rank hold SPRO as of Q4 2020.

  • STRS Ohio reported no remaining Spero Therapeutics position as of Q4 2020 after selling out during the quarter.
  • STRS Ohio sold 7,100 Spero Therapeutics shares in Q4 2020, an estimated $79K.
  • STRS Ohio first reported a position in Spero Therapeutics in Q4 2017 and held it in 5 quarters.
  • STRS Ohio's Spero Therapeutics position peaked at $96K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2020.

Based on STRS Ohio's 13F filing for Q4 2020, filed 25 Jan 2021.